Christopher Dufton

2.4k total citations · 1 hit paper
32 papers, 1.7k citations indexed

About

Christopher Dufton is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christopher Dufton has authored 32 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cardiology and Cardiovascular Medicine, 17 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Christopher Dufton's work include Pulmonary Hypertension Research and Treatments (17 papers), Renin-Angiotensin System Studies (8 papers) and Atrial Fibrillation Management and Outcomes (6 papers). Christopher Dufton is often cited by papers focused on Pulmonary Hypertension Research and Treatments (17 papers), Renin-Angiotensin System Studies (8 papers) and Atrial Fibrillation Management and Outcomes (6 papers). Christopher Dufton collaborates with scholars based in United States, Netherlands and United Kingdom. Christopher Dufton's co-authors include Ronald J. Oudiz, Lewis J. Rubin, Horst Olschewski, Hossein Ardeschir Ghofrani, Adaani Frost, Michael D. McGoon, David B. Badesch, Vallerie V. McLaughlin, Ellen B. Roecker and Nazzareno Galiè and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Journal of the American College of Cardiology.

In The Last Decade

Christopher Dufton

32 papers receiving 1.6k citations

Hit Papers

Ambrisentan for the Treatment of Pulmonary Arterial Hyper... 2008 2026 2014 2020 2008 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
    2008 785 citations Nazzareno Galiè, Horst Olschewski et al. Circulation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Dufton United States 17 1.4k 999 241 225 168 32 1.7k
Marie‐Camille Chaumais France 24 1.2k 0.9× 618 0.6× 277 1.1× 169 0.8× 145 0.9× 64 1.8k
Michelle Turner United States 11 1.6k 1.2× 1.0k 1.0× 422 1.8× 173 0.8× 78 0.5× 26 1.9k
NORBERT F. VOELKEL United States 7 1.3k 0.9× 445 0.4× 148 0.6× 155 0.7× 228 1.4× 8 1.6k
R. James White United States 19 2.6k 1.9× 1.7k 1.7× 488 2.0× 328 1.5× 172 1.0× 63 2.9k
Ralph Preiss United States 11 992 0.7× 664 0.7× 160 0.7× 120 0.5× 60 0.4× 16 1.3k
B.K.S. Sastry India 10 1.6k 1.2× 1.2k 1.2× 339 1.4× 168 0.7× 160 1.0× 18 1.8k
Massimiliano Palazzini Italy 21 2.4k 1.7× 1.7k 1.7× 394 1.6× 182 0.8× 73 0.4× 69 2.6k
Natalie Doughty United Kingdom 11 1.1k 0.8× 632 0.6× 183 0.8× 121 0.5× 65 0.4× 20 1.2k
Gerd Staehler Germany 20 1.2k 0.9× 641 0.6× 86 0.4× 71 0.3× 90 0.5× 36 1.8k
Carmen Treacy United Kingdom 10 1.2k 0.8× 621 0.6× 199 0.8× 96 0.4× 61 0.4× 17 1.3k

Countries citing papers authored by Christopher Dufton

Since Specialization
Citations

This map shows the geographic impact of Christopher Dufton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Dufton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Dufton more than expected).

Fields of papers citing papers by Christopher Dufton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Dufton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Dufton. The network helps show where Christopher Dufton may publish in the future.

Co-authorship network of co-authors of Christopher Dufton

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Dufton. A scholar is included among the top collaborators of Christopher Dufton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Dufton. Christopher Dufton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rienstra, Michiel, Aaf F.M. Kuijper, Sabine Eijsbouts, et al.. (2025). Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial. EP Europace. 27(4). 1 indexed citations
2.
Dufton, Christopher, Marc Evanchik, David G. Daniel, et al.. (2025). EDG-7500, A First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, And Pharmacokinetics In Healthy Adults. Journal of Cardiac Failure. 31(1). 345–345. 3 indexed citations
3.
Ruskin, Jeremy N., A. John Camm, Christopher Dufton, et al.. (2024). Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm. JACC. Clinical electrophysiology. 10(6). 1021–1033. 10 indexed citations
4.
Abraham, William T., Jonathan P. Piccini, Christopher Dufton, et al.. (2021). Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial. Heart Rhythm O2. 3(1). 40–49. 1 indexed citations
5.
6.
Gomberg‐Maitland, Mardi, Christopher Dufton, Ronald J. Oudiz, & Raymond L. Benza. (2011). Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?. Journal of the American College of Cardiology. 57(9). 1053–1061. 50 indexed citations
7.
Venitz, Jürgen, et al.. (2011). Clinical Pharmacokinetics and Drug‐Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. The Journal of Clinical Pharmacology. 52(12). 1784–1805. 52 indexed citations
8.
Badesch, David B., Jeremy Feldman, Anne Keogh, et al.. (2011). ARIES‐3: Ambrisentan Therapy in a Diverse Population of Patients with Pulmonary Hypertension. Cardiovascular Therapeutics. 30(2). 93–99. 64 indexed citations
9.
Harrison, Brooke C., Mindy Magee, Arun Mandagere, et al.. (2010). Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects. Clinical Drug Investigation. 30(12). 875–885. 16 indexed citations
10.
Spence, Rebecca, Arun Mandagere, Duncan Richards, et al.. (2010). Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine. Clinical Pharmacology & Therapeutics. 88(4). 513–520. 25 indexed citations
11.
Spence, Rebecca, Arun Mandagere, Gennyne Walker, Christopher Dufton, & Ramesh Boinpally. (2010). Effect of Steady-State Ambrisentan on the Pharmacokinetics of a Single Dose of the Oral Contraceptive Norethindrone (Norethisterone) 1 mg/Ethinylestradiol 35 μg in Healthy Subjects. Clinical Drug Investigation. 30(5). 313–324. 13 indexed citations
12.
Oudiz, Ronald J., Nazzareno Galiè, Horst Olschewski, et al.. (2009). Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology. 54(21). 1971–1981. 176 indexed citations
13.
Walker, Gennyne, Arun Mandagere, Christopher Dufton, & Jürgen Venitz. (2009). The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. British Journal of Clinical Pharmacology. 67(5). 527–534. 31 indexed citations
14.
Spence, Rebecca, Arun Mandagere, Brooke C. Harrison, Christopher Dufton, & Ramesh Boinpally. (2009). No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. Journal of Pharmaceutical Sciences. 98(12). 4962–4974. 50 indexed citations
15.
Galiè, Nazzareno, Horst Olschewski, Ronald J. Oudiz, et al.. (2008). Ambrisentan for the Treatment of Pulmonary Arterial Hypertension. Circulation. 117(23). 3010–3019. 785 indexed citations breakdown →
16.
Rubin, Lewis J., Christopher Dufton, & Michael J. Gerber. (2005). Ambrisentan for Pulmonary Arterial Hypertension. Future Cardiology. 1(4). 425–432. 17 indexed citations
17.
Stemmer, Salomon M., Pablo J. Cagnoni, Elizabeth J. Shpall, et al.. (1996). High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial.. Journal of Clinical Oncology. 14(5). 1463–1472. 53 indexed citations
18.
Stemmer, Salomon M., Ravindra Kasliwal, James L. Lear, et al.. (1995). High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial.. PubMed. 55(23 Suppl). 5921s–5924s. 38 indexed citations
19.
Jones, R.B., S Matthes, E.J. Shpall, et al.. (1993). Acute Lung Injury Following Treatment With High-Dose Cyclophosphamide, Cisplatin, and Carmustine: Pharmacodynamic Evaluation of Carmustine. JNCI Journal of the National Cancer Institute. 85(8). 640–647. 67 indexed citations
20.
Jones, Roy B., S Matthes, Christopher Dufton, et al.. (1993). Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. Breast Cancer Research and Treatment. 26(1). S11–S17. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie‐Camille Chaumais Breakdown of academic impact, for papers by Michelle Turner Breakdown of academic impact, for papers by NORBERT F. VOELKEL Breakdown of academic impact, for papers by R. James White Breakdown of academic impact, for papers by Ralph Preiss Breakdown of academic impact, for papers by B.K.S. Sastry Breakdown of academic impact, for papers by Massimiliano Palazzini Breakdown of academic impact, for papers by Natalie Doughty Breakdown of academic impact, for papers by Gerd Staehler Breakdown of academic impact, for papers by Carmen Treacy
Rankless by CCL
2026